Effects of L-arginine on the Oxidative System in Breast Cancer Mcf-7 Cells
Name: LUCAS ANDRE SILVA BONELA
Publication date: 26/03/2020
Advisor:
Name |
Role |
|---|---|
| SONIA ALVES GOUVEA | Advisor * |
Examining board:
| Name |
Role |
|---|---|
| ADRIANA MADEIRA ALVARES DA SILVA | Internal Examiner * |
| MARCELO PERIM BALDO | External Examiner * |
| SONIA ALVES GOUVEA | Advisor * |
Summary: The use of L-arginine (L-ARG) in the dietary supplementation of cancer patients has shown positive results due to its relevance in different systems of the body, but its use can have direct effects on tumor cells. Therapeutic approaches against cancer have been the subject of several studies, as in many cases the forms of treatments are effective, but comorbidities are aggravating for prognosis and survival, including breast cancer. However, in vitro, the association of L-ARG with other molecules has been shown to be effective in reducing the growth of tumor cells, in addition to improving the immune response of patients. Thus, the use of MCF-7 breast tumor cells may show the effects of different doses of L-ARG on the cellular oxidative system. The treatment consisted of exposure to concentrations 800/1600/3200 µg / mL of L-ARG for 48 hours. The AlamarBlue® assay was used to measure proliferation and assess cell viability. Evaluation of the catalase expression, the gp91phox subunit, and CtIP, was performed by Western blot and the ImageJ software was used to measure the amount of each protein. The data were analyzed using the GraphPad Prism® 8.0.2 software and using the one-way ANOVA test. The changes in MCF-7 cells were: increased amount of the gp91phox subunit, reduced catalase and increased amount of CtIP time dependent dose. Treatment with L-ARG in MCF-7 tumor cells reduced CAT expression, increased gp91phox and CtIP. At the 3200µg / mL dose, there was a reduction in cell viability. These results may contribute to the association of L-ARG with conventional therapies in the treatment of breast cancer.
